Impact of renal function on platelet aggregation: a comparative study of prasugrel and clopidogrel
Authors' conclusion
In patients with impaired renal function, prasugrel provided a more rapid reduction in platelet aggregation compared with clopidogrel, particularly during the early phase of antiplatelet treatment. Further research is needed to confirm these findings in larger and more diverse populations.
Study context
- Population
- Patients with stable coronary artery disease (CAD) undergoing dual antiplatelet therapy
- Participants
- 164 patients
- Comparison
- Prasugrel vs clopidogrel, by estimated glomerular filtration rate (eGFR)
- Primary endpoint
- Inhibition of platelet aggregation (PRU), eGFR <45 group
- Follow-up
- Day 5 and day 30
Methodological detailsstratified by eGFR
- Stratified by eGFR
Primary result
As reported in the abstract
| Group | Baseline | Day 5 | Day 30 |
|---|---|---|---|
| Clopidogrel | 198.2 | 214.2 | 200.0 |
| Prasugrel | 177.2 | 157.9 | 141.7 |
Baseline
Clopidogrel198.2
Prasugrel177.2
Day 5
Clopidogrel214.2
Prasugrel157.9
Day 30
Clopidogrel200.0
Prasugrel141.7
- Clopidogrel vs prasugrel: P = 0.036 — day 5
- Clopidogrel vs prasugrel: P = 0.105 — day 30
Original publication
Impact of renal function on platelet aggregation: a comparative study of prasugrel and clopidogrel. Heart. Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →